Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | BMP1 | P13497 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | TLR4 | O00206 | 2/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.32 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5434632 | 0.97 | CCR1 (0.39) | CCR1ADAM17EPHX2BMP1PIK3CA | |
| SCHEMBL4141707 | 0.89 | CCR1 (0.39) | CCR1ADAM17EPHX2BMP1PIK3CA | |
| SCHEMBL4142970 | 0.88 | CCR1 (0.39) | CCR1ADAM17EPHX2BMP1PIK3CA | |
| SCHEMBL4127283 | 0.88 | EPHX2 (0.42) | CCR1ADAM17EPHX2BMP1PIK3CA | |
| SCHEMBL4130817 | 0.87 | CCR1 (0.38) | CCR1ADAM17EPHX2BMP1HSD11B1 | |
| SCHEMBL4140995 | 0.87 | CCR1 (0.38) | CCR1ADAM17EPHX2BMP1HSD11B1 | |
| SCHEMBL4140822 | 0.87 | CCR1 (0.38) | CCR1ADAM17EPHX2BMP1PIK3CA | |
| SCHEMBL5429196 | 0.86 | CCR1 (0.40) | CCR1ADAM17EPHX2BMP1PIK3CA | |
| SCHEMBL4141981 | 0.86 | CCR1 (0.37) | CCR1ADAM17EPHX2BMP1PIK3CA | |
| SCHEMBL4128183 | 0.86 | CCR1 (0.37) | CCR1ADAM17EPHX2BMP1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | claimed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | CCR1 766/4885ADAM17 2364/4885EPHX2 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.